RxDoctor Payments Data

Cheri Call, APRN

Family · South Charleston, WVNPI 1043706872

Payments from drug & device makers

$6,465in general payments, 2019–2025

Across 335 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$801
  • Otsuka America Pharmaceutical, Inc.$675
  • Lundbeck LLC$446
  • Axsome Therapeutics, Inc.$444
  • Takeda Pharmaceuticals U.S.A., Inc.$417
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,465 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$17,873
Medicare patients
58
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl26$44,892
Abilify MaintenaAripiprazole12$26,861
PristiqDesvenlafaxine Succinate12$4,944
Lisdexamfetamine Dimesylate16$2,640
Atomoxetine Hcl13$1,568
Aripiprazole88$1,522
Duloxetine Hcl77$1,123
Ziprasidone Hcl43$1,117
Clonazepam170$1,003
Quetiapine Fumarate91$964
Trazodone Hcl83$936
Venlafaxine Hcl ErVenlafaxine Hcl74$865
Lamotrigine91$783
Carbamazepine14$681
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,414$44,89226 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$675$26,86112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →